



NDA 20-903/S-025

Schering Corporation
Attention: Mary Jane Nehring
Senior Director, Marketed Products Support and Training
Worldwide Regulatory Affairs
2000 Galloping Hill Road
Kenilworth, NJ 07033

Dear Ms. Nehring,

Please refer to your supplemental new drug application dated February 7, 2002, received February 8, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for REBETOL® (ribavirin) capsules for use in combination with the approved biologic product Intron®A (interferon alfa 2b) (REBETRON COMBINATION THERAPY™).

We acknowledge receipt of your submissions dated March 29, 2002, April 22, 2002, June 26, 2002, August 12, 2002, and October 11, 2002.

This "Changes Being Effected" supplemental new drug application provides for:

1. The inclusion of information in the Warnings section of the REBETRON COMBINATION THERAPY™ and REBETOL® labels, regarding the possible occurrence or exacerbation of sarcoidosis.
2. A revision of the renal clearance statements in the REBETRON COMBINATION THERAPY™ label, to provide consistency with the renal clearance statements that are in the REBETOL® label.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package inserts submitted October 11, 2002, patient package inserts submitted October 11, 2002).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-903/S-025." Approval of this submission by FDA is not required before the labeling is used. In addition, please submit three copies of the introductory promotional materials that you

propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Nitin Patel, R.Ph., Regulatory Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ATTACHMENT:

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Jeffrey Murray

11/13/02 12:52:00 PM